: The AMEDEO Literature Guide

Home The Word Brain

My Amedeo

FAQ

Privacy

About

C49 + CC Journal Club

For more information, please refer to our special emails from April 13 and May 19.

Lung Cancer

Free Subscription

Articles published in BMC Cancer
Retrieve available abstracts of 392 articles:
HTML format

Single Articles

May 2025

HONG M, Yun I, Moon JY
Impact of doctor-shopping behavior on patient survival in lung cancer: findings from a 11-year cohort study using Korean claims data.
BMC Cancer. 2025;25:914.
PubMed Abstract available

YANG S, Liu Y, Zhao J, He Z, et al
EGFR exon 20 insertions mutation in lung adenocarcinoma and its response by high-dose of Furmonertinib: a real-world study.
BMC Cancer. 2025;25:900.
PubMed Abstract available

ZHENG C, Miao J, Xu L, Cai Y, et al
Novel PET imaging biomarkers as predictors of postoperative recurrence in lung adenocarcinoma.
BMC Cancer. 2025;25:874.
PubMed Abstract available

CHEN X, Wang K, Liao Y, Zheng C, et al
Safety and efficacy of rechallenge with immune checkpoint inhibitors and anlotinib in advanced non-small cell lung cancer without targetable driver mutations: a retrospective analysis.
BMC Cancer. 2025;25:862.
PubMed Abstract available

YAO J, Geng Y, Xu J, Zou B, et al
The impact of EGFR mutation and PD-L1 status on the efficacy of postoperative radiotherapy in stage III-pN2 NSCLC.
BMC Cancer. 2025;25:858.
PubMed Abstract available

ZHAO S, Du X, Zhang Y, Bai J, et al
Development and application of a whole transcriptome sequencing assay for the detection of gene fusions in clinical cancer specimens.
BMC Cancer. 2025;25:842.
PubMed Abstract available

ZHANG J, Zhang Z, Liu Y, Hou Y, et al
Metabolic characteristics of benign and malignant pulmonary nodules and establishment of invasive lung adenocarcinoma model by high-resolution mass spectrometry.
BMC Cancer. 2025;25:844.
PubMed Abstract available

ZHAO F, Bai H, Liu Y, Gao S, et al
FLT3LG modulates the infiltration of immune cells and enhances the efficacy of anti-PD-1 therapy in lung adenocarcinoma.
BMC Cancer. 2025;25:831.
PubMed Abstract available

DONG J, Qi Y, Sha S, Fu C, et al
Whole-body CT scanning radiation improves the immune microenvironment of tumor tissues to enhance the antitumor effect of ICI.
BMC Cancer. 2025;25:824.
PubMed Abstract available

HAJIKARIMLOO B, Mohammadzadeh I, Tos SM, Habibi MA, et al
Machine learning in prediction of epidermal growth factor receptor status in non-small cell lung cancer brain metastases: a systematic review and meta-analysis.
BMC Cancer. 2025;25:818.
PubMed Abstract available

April 2025

KUANG S, Xiao S, Zhou J, Liu L, et al
Combined effect of areca nut, cigarettes, alcohol and SNPs in glycosyltransferase family genes on lung cancer development in Hainan, China.
BMC Cancer. 2025;25:814.
PubMed Abstract available

LIAO J, Hu X, Wei X, Dai W, et al
Sex-related differences in postoperative patient-reported outcomes among lung cancer patients: a multicenter cohort study.
BMC Cancer. 2025;25:800.
PubMed Abstract available

ZHU Q, Hu H, OuYang LY, Yang R, et al
The association of PD-L1 expression status and the PD-1/PD-L1 inhibitor-related toxicity profile in non-small cell lung cancer.
BMC Cancer. 2025;25:799.
PubMed Abstract available

WANG Y, Ma X, Ma J, Li J, et al
Thyroid dysfunction as a predictor of PD- 1/PD-L1 inhibitor efficacy in advanced lung cancer.
BMC Cancer. 2025;25:791.
PubMed Abstract available

OU G, Gao T, Hu S, Zhang S, et al
Comprehensive pan-cancer analysis of CHRDL1 and experimental validation of its role in lung adenocarcinoma.
BMC Cancer. 2025;25:783.
PubMed Abstract available

LI S, Huang Z, Zhong X, Zhou Y, et al
The real-world safety profile of pemetrexed and platinum with or without pembrolizumab: insights from a comparative analysis of FAERS database.
BMC Cancer. 2025;25:767.
PubMed Abstract available

MINE H, Sugimoto K, Kobayashi M, Takagi H, et al
Abnormal phosphorylation of human LRH1 at Ser510 predicts poor prognosis and promotes cell viability in lung squamous cell carcinoma.
BMC Cancer. 2025;25:764.
PubMed Abstract available

DAI L, Huang L, Li L, Tang L, et al
Pretreatment plasma sCD14 as a prognostic indicator in advanced non-small cell lung cancer patients undergoing immunotherapy.
BMC Cancer. 2025;25:763.
PubMed Abstract available

TANG F, Cao XJ, Gong T, Huang XY, et al
Bronchial arterial chemoembolization/infusion combined with iodine-125 brachytherapy in advanced non-small cell lung cancer: a promising salvage therapy after standard treatment failure.
BMC Cancer. 2025;25:750.
PubMed Abstract available

HOU Y, Xue X, Zhang Z, Mai D, et al
Genomic and clinical characterization of HER2 exon 20 mutations in non-small cell lung cancer: insights from a multicenter study in South China.
BMC Cancer. 2025;25:752.
PubMed Abstract available

WU S, Guo Y, Wang R
Combining network pharmacology and experimental verification to explore the inhibitory effects of Deoxyelephantopin (DET) Against Non-Small Cell Lung Cancer (NSCLC).
BMC Cancer. 2025;25:738.
PubMed Abstract available

ZHANG X, Zhang L, Geng Z, Shang M, et al
Potential profile analysis of financial toxicity and its related factors among lung cancer patients.
BMC Cancer. 2025;25:740.
PubMed Abstract available

HU D, Hu Y, Lei S, Wu D, et al
MET tyrosine kinase inhibitors in combination with EGFR tyrosine kinase inhibitors in NSCLC patients with EGFR mutations and acquired MET alterations: a systematic review and meta-analysis.
BMC Cancer. 2025;25:732.
PubMed Abstract available

LIU C, He Y, Luo J
The influence of image selection and segmentation on the extraction of lung cancer imaging radiomics features using 3D-Slicer software.
BMC Cancer. 2025;25:728.
PubMed Abstract available

WANG FY, Yeh YC, Lin SY, Wang SY, et al
Real-world application of targeted next-generation sequencing for identifying molecular variants in Asian non-small-cell lung cancer.
BMC Cancer. 2025;25:715.
PubMed Abstract available

GAO Y, Hu P, Wu N, Tan F, et al
A study protocol for the CHinA National CancEr screening (CHANCES) trial: a randomized controlled study to compare the screening strategies for lung cancer and colorectal cancer.
BMC Cancer. 2025;25:727.
PubMed Abstract available

LIAO S, Sun H, Lu H, Wu J, et al
Neutrophil-to-lymphocyte ratio-based prognostic score can predict outcomes in patients with advanced non-small cell lung cancer treated with immunotherapy plus chemotherapy.
BMC Cancer. 2025;25:697.
PubMed Abstract available

FAN Z, Liu W, Gao Z, Liu Y, et al
CMSS1: A RNA binding protein with pivotal roles in non-small cell lung cancer progression and prognosis.
BMC Cancer. 2025;25:688.
PubMed Abstract available

XU J, Zhang Z, Han K, Yang Z, et al
EXOSC5: a novel biomarker for poor prognosis in lung adenocarcinoma.
BMC Cancer. 2025;25:681.
PubMed Abstract available

LI Z, Miao H, Bao W, Zhang L, et al
Development and validation of a nomogram model of lung metastasis in breast cancer based on machine learning algorithm and cytokines.
BMC Cancer. 2025;25:692.
PubMed Abstract available

KONDO N, Yoshiura T, Kakinohana Y, Yamashita M, et al
Risk factors for radiation-induced rib fractures following proton beam therapy for stage I non-small cell lung cancer: a retrospective study.
BMC Cancer. 2025;25:682.
PubMed Abstract available

CAO W, Han S, Zhang P, Mi L, et al
Immune checkpoint inhibitor-related myocarditis in patients with lung cancer.
BMC Cancer. 2025;25:685.
PubMed Abstract available

LEI Y, Cao C, Tang R, Liu Y, et al
Peripheral blood inflammatory biomarkers neutrophil/ lymphocyte ratio, platelet/lymphocyte ratio and systemic immune-inflammation index/albumin ratio predict prognosis and efficacy in non-small cell lung cancer patients receiving immunotherapy and opi
BMC Cancer. 2025;25:664.
PubMed Abstract available

MEI K, Feng Z, Liu H, Wang M, et al
Preoperative prediction of pulmonary ground-glass nodule infiltration status by CT-based radiomics combined with neural networks.
BMC Cancer. 2025;25:659.
PubMed Abstract available

TAJE R, Gallina FT, Caterino M, Forcella D, et al
Molecular characterization of early-stage lung adenocarcinoma presenting as subsolid nodules in a real-life European cohort.
BMC Cancer. 2025;25:647.
PubMed Abstract available

LI J, Xu HL, Li WX, Ma XY, et al
Prognostic factors of survival in patients with lung cancer after low-dose computed tomography screening: a multivariate analysis of a lung cancer screening cohort in China.
BMC Cancer. 2025;25:646.
PubMed Abstract available

XU S, Yin SY, Bie ZX, Li YM, et al
Personalized drug screening of patient-derived tumor-like cell clusters based on specimens obtained from percutaneous transthoracic needle biopsy in patients with lung malignancy: a real-world study.
BMC Cancer. 2025;25:649.
PubMed Abstract available

SANG H, Liu J, Chen X, Zeng Y, et al
METTL16-dependent miR-146b-5p m6A modification remodeling sensitize NSCLC to osimertinib via activating PI3K/AKT signaling.
BMC Cancer. 2025;25:641.
PubMed Abstract available

YIN X, Lin X, Zhang G, Yin Y, et al
Intensity-modulated proton therapy for hippocampal-sparing prophylactic cranial irradiation: a planning comparison with photon therapy.
BMC Cancer. 2025;25:639.
PubMed Abstract available

LI Y, Zhou J, Liu L, Zhu C, et al
Association of SNPs in nAChRs genes, areca nut chewing and smoking, and their interaction with lung cancer in Hainan, China: a case control study.
BMC Cancer. 2025;25:626.
PubMed Abstract available

CAPDEVILA J, Pubul V, Anido U, Walter T, et al
A Randomized clinical trial evaluating the impact on survival and quality of life of (177)Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217).
BMC Cancer. 2025;25:613.
PubMed Abstract available

GUO RQ, Li YM, Bie ZX, Peng JZ, et al
Microwave ablation of non-small cell lung cancer enhances local T-cell abundance and alters monocyte interactions.
BMC Cancer. 2025;25:605.
PubMed Abstract available

ZHENG W, Zhou C, Xue Z, Qiao L, et al
Integrative analysis of a novel signature incorporating metabolism and stemness-related genes for risk stratification and assessing clinical outcomes and therapeutic responses in lung adenocarcinoma.
BMC Cancer. 2025;25:591.
PubMed Abstract available

March 2025

WU S, Jiang R, Fedorowicz G, Wong M, et al
Analytical validation of the Percepta Nasal Swab classifier; an RNA next-generation sequencing assay for the assessment of lung cancer risk in pulmonary nodules.
BMC Cancer. 2025;25:577.
PubMed Abstract available

THOMPSON JJ, MacLeod N, Will S, O'Rourke F, et al
The prognostic value of a laboratory cachexia score (LCAS) defined by LDH, CRP and albumin in patients with advanced lung cancer.
BMC Cancer. 2025;25:543.
PubMed Abstract available

LI S, Du F, Zhang Y, Wang Q, et al
Myocarditis prediction in locally advanced or metastatic lung cancer patients with cardiac parameters abnormalities undergoing immunotherapy: development and validation of a risk assessment model.
BMC Cancer. 2025;25:541.
PubMed Abstract available

PAN X, Deng H
Deubiquitinase USP18 mediates cell migration, apoptosis and ferroptosis in lung adenocarcinoma by depending on POU4F1/PRKAA2 axis.
BMC Cancer. 2025;25:528.
PubMed Abstract available

ZHU ZY, Yun YQ, Li H, Qin ZQ, et al
Subpleural injection of gelatin sponge particles to reduce pneumothorax incidence in CT-guided lung biopsies: a retrospective single-center case-control study.
BMC Cancer. 2025;25:529.
PubMed Abstract available

LIU X, Ji Z, Zhang L, Li L, et al
Prediction of pathological complete response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer using (18)F-FDG PET radiomics features of primary tumour and lymph nodes.
BMC Cancer. 2025;25:520.
PubMed Abstract available

LIU X, Yin X, Zhuang L, Wen J, et al
Efficacy and safety of TQB2450 combined with anlotinib as maintenance therapy for LS-SCLC after definitive concurrent or sequential chemoradiotherapy: a prospective phase Ib study.
BMC Cancer. 2025;25:509.
PubMed Abstract available

CAO L, Li T, Xu X, Sun M, et al
Texasin, A main product from Caragana Jubata (Pall.) Poir, induces proliferation arrest and protective autophagy in lung adenocarcinoma.
BMC Cancer. 2025;25:513.
PubMed Abstract available

HE D, Lu H, Ou X, Zheng T, et al
Correction: Exposure to major coronary heart disease events reduces lung cancer risk: a Mendelian randomization study based on a European population.
BMC Cancer. 2025;25:501.
PubMed

LIN W, Wang Y, Li M, Feng J, et al
Tumor treating fields enhance anti-PD therapy by improving CCL2/8 and CXCL9/CXCL10 expression through inducing immunogenic cell death in NSCLC models.
BMC Cancer. 2025;25:489.
PubMed Abstract available

SHI Y, Wang X, Pei Z, Shi H, et al
Telpegfilgrastim for chemotherapy-induced neutropenia in patients with non-small cell lung cancer: a multicentre, randomized, phase 3 study.
BMC Cancer. 2025;25:490.
PubMed Abstract available

LI Y, Liu Y, Xie Y, Wang Y, et al
Long-read RNA sequencing enables full-length chimeric transcript annotation of transposable elements in lung adenocarcinoma.
BMC Cancer. 2025;25:482.
PubMed Abstract available

LI Y, Tong Z, Yang Y, Wang Y, et al
Lung Cancer Biomarker Database (LCBD): a comprehensive and curated repository of lung cancer biomarkers.
BMC Cancer. 2025;25:478.
PubMed Abstract available

ZHAO K, Lu S, Niu J, Zhu H, et al
Real-world data on immunotherapy combined with chemotherapy in elderly patients with extensive-stage small cell lung cancer.
BMC Cancer. 2025;25:467.
PubMed Abstract available

CAI F, Guo Z, Wang G, Luo F, et al
Integration of intratumoral and peritumoral CT radiomic features with machine learning algorithms for predicting induction therapy response in locally advanced non-small cell lung cancer.
BMC Cancer. 2025;25:461.
PubMed Abstract available

WU T, Cai J, Li Y, Xie R, et al
Validation for revision of the stage IIIA(T1N2) in the forthcoming ninth edition of the TNM classification for lung cancer.
BMC Cancer. 2025;25:446.
PubMed Abstract available

CAO P, Jia X, Wang X, Fan L, et al
Deep learning radiomics for the prediction of epidermal growth factor receptor mutation status based on MRI in brain metastasis from lung adenocarcinoma patients.
BMC Cancer. 2025;25:443.
PubMed Abstract available

WEI K, Sun T, Feng X, Chen Y, et al
PD-1/L1 immune checkpoint inhibitors for KRAS-mutant non-small cell lung cancer: a multicenter retrospective real-world study.
BMC Cancer. 2025;25:444.
PubMed Abstract available

JAHANI MM, Mashayekhi P, Omrani MD, Meibody AA, et al
Efficacy of liquid biopsy for genetic mutations determination in non-small cell lung cancer: a systematic review on literatures.
BMC Cancer. 2025;25:433.
PubMed Abstract available

ZHANG Z, Zhao Y, Ma YJ, Chen CQ, et al
Prediction of STAS in lung adenocarcinoma with nodules
BMC Cancer. 2025;25:417.
PubMed Abstract available

LAI Z, Pang Y, Zhou Y, Chen L, et al
Luteolin as an adjuvant effectively enhanced the efficacy of adoptive tumor-specific CTLs therapy.
BMC Cancer. 2025;25:411.
PubMed Abstract available

LAI Y, Zhou S, Tian L, Li H, et al
Preoperative heart rate variability as a predictor of postoperative pneumonia and lung function recovery in surgical lung cancer patients: a prospective observed study.
BMC Cancer. 2025;25:404.
PubMed Abstract available

ZHANG L, Luo J, Wu X
Impact of single-port versus three-port video-assisted thoracic surgery lobectomy on postoperative pain and quality of life in early-stage non-small cell lung cancer patients: a meta-analysis.
BMC Cancer. 2025;25:400.
PubMed Abstract available

NIE X, Zou M, Song C, Zhang P, et al
Survival impact and risk factors of skeletal muscle loss during first-line EGFR-TKIs therapy in advanced lung adenocarcinoma patients.
BMC Cancer. 2025;25:393.
PubMed Abstract available

SHIMA Y, Yoshida H, Suminaga K, Yoshida H, et al
Safety and efficacy of pemetrexed for patients with non-small cell lung cancer in the setting of renal impairment: a retrospective study.
BMC Cancer. 2025;25:388.
PubMed Abstract available

ZHI L, Zhang Z, Gao Q, Shang C, et al
Correction: CAR-NK cells with dual targeting of PD-L1 and MICA/B in lung cancer tumor models.
BMC Cancer. 2025;25:386.
PubMed

February 2025

OH JH, Lee SJ, Park YJ
F-18 FDG PET-derived imaging biomarkers of airway inflammation and their clinical associations in patients with non-small cell lung cancer.
BMC Cancer. 2025;25:379.
PubMed Abstract available

HUANG F, Lin X, Hong Y, Li Y, et al
The feasibility and cost-effectiveness of implementing mobile low-dose computed tomography with an AI-based diagnostic system in underserved populations.
BMC Cancer. 2025;25:345.
PubMed Abstract available

ZHI L, Zhang Z, Gao Q, Shang C, et al
CAR-NK cells with dual targeting of PD-L1 and MICA/B in lung cancer tumor models.
BMC Cancer. 2025;25:337.
PubMed Abstract available

GAO H, Zou X, Fan M, Chen M, et al
Predictive model for sarcopenia in patients with non-small cell lung cancer and malignant pleural effusion.
BMC Cancer. 2025;25:350.
PubMed Abstract available

IEMWIMANGSA N, Anantaya D, Oranratnachai S, Thamrongjirapat T, et al
Dynamic changes in immune repertoire profiles in patients with stage III unresectable non-small cell lung cancer during consolidation treatment with immunotherapy.
BMC Cancer. 2025;25:333.
PubMed Abstract available

BAO T, Deng Y, Chen L, Sun W, et al
Primary tumour resection in non-small cell lung cancer patients with pleural dissemination unexpectedly detected during operation: a two-centre retrospective cohort study.
BMC Cancer. 2025;25:316.
PubMed Abstract available

HUANG Z, Wang H, Ting F, Chen Y, et al
Metabolic and multi-model intravoxel incoherent motion parameters based (18)F-FDG PET/MRI for predicting subtypes of inoperable non-small cell lung cancer.
BMC Cancer. 2025;25:322.
PubMed Abstract available

YANG Y, Li X, Duan Y, Zhao J, et al
Risk factors for malignant solid pulmonary nodules: a meta-analysis.
BMC Cancer. 2025;25:312.
PubMed Abstract available

WANG X, Wu YX, Hu WP, Zhang J, et al
Incidence and risk factors of serious infections occurred in patients with lung cancer following immune checkpoint blockade therapy.
BMC Cancer. 2025;25:307.
PubMed Abstract available

CHEN W, Gao P, Lu F, Wang E, et al
CT texture features of lung adenocarcinoma with HER2 mutation.
BMC Cancer. 2025;25:287.
PubMed Abstract available

FUKUSHIMA T, Katsushima U, Ogushi N, Hase K, et al
Lower-extremity muscle strength is associated with prognosis in patients with advanced or recurrent lung cancer: a retrospective, observational study.
BMC Cancer. 2025;25:282.
PubMed Abstract available

XINJING Z, Lei G, Xinbao L, Zhonghe J, et al
Prognostic importance of the neutrophil-to-lymphocyte ratio in malignant peritoneal mesothelioma patients receiving cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
BMC Cancer. 2025;25:270.
PubMed Abstract available

WANG H, Chen K, Ma S, Huang W, et al
PPIs effect in EGFR-TKI-associated interstitial lung diseases in patients with non-small cell lung cancer.
BMC Cancer. 2025;25:263.
PubMed Abstract available

YANG X, Song Y, Xu R, Yang Y, et al
Prophylactic cranial irradiation improved the prognosis in pT1-2N0M0 small cell lung cancers after complete resection: a retrospective real-world study.
BMC Cancer. 2025;25:266.
PubMed Abstract available

DU CC, Sun DQ, Chen YX, Li JS, et al
Study of the microenvironment of the lung flora in female lung adenocarcinoma patients: from benign lesions to invasive lung adenocarcinomas.
BMC Cancer. 2025;25:252.
PubMed Abstract available

ZHANG P, Wang L, Liu H, Lin S, et al
Unveiling the crucial role of glycosylation modification in lung adenocarcinoma metastasis through artificial neural network-based spatial multi-omics single-cell analysis and Mendelian randomization.
BMC Cancer. 2025;25:249.
PubMed Abstract available

WU D, Huang Y, Wang B, Zheng Q, et al
A clinical model to predict brain metastases in resected early-stage non-small cell lung cancer.
BMC Cancer. 2025;25:236.
PubMed Abstract available

JIANG Y, Hu X, Heibi Y, Wu H, et al
Exploring prognostic precision: a nomogram approach for malignant pleural effusion in lung cancer.
BMC Cancer. 2025;25:227.
PubMed Abstract available

CHEN H, Xu Y, Chen D, Xiao D, et al
The Hippo pathway promotes platinum-based chemotherapy by inhibiting MTF1-dependent heavy metal response.
BMC Cancer. 2025;25:223.
PubMed Abstract available

GAO R, Liang W, Chen J, Yang M, et al
Comparisons of adverse events associated with immune checkpoint inhibitors in the treatment of non-small cell lung cancer: a real-world disproportionality analysis based on the FDA adverse event reporting system.
BMC Cancer. 2025;25:216.
PubMed Abstract available

KRAFT A, Kirschner MB, Orlowski V, Ronner M, et al
Exploring RNA cargo in extracellular vesicles for pleural mesothelioma detection.
BMC Cancer. 2025;25:212.
PubMed Abstract available

QU J, Chen Z, Zhu Y, Huang J, et al
Pulmonary Nuclear protein in Testis (NUT) carcinoma: clinical, molecular characteristics, and treatment strategies.
BMC Cancer. 2025;25:196.
PubMed Abstract available

January 2025

ZHANG D, Liu G, Ye J, Li K, et al
Low-exhaustion peripheral circulating gammadelta T cells serve as a biomarker for predicting the clinical benefit rate of non-small cell lung cancer (NSCLC) patients to chemotherapy or targeted therapy: a single-center retrospective study.
BMC Cancer. 2025;25:178.
PubMed Abstract available

LUO L, Ji J, Dong J, He M, et al
Infiltration and subtype analysis of CD3 + CD20 + T cells in lung cancer.
BMC Cancer. 2025;25:179.
PubMed Abstract available

HE D, Lu H, Ou X, Zheng T, et al
Exposure to major coronary heart disease events reduces lung cancer risk: a mendelian randomization study based on a European population.
BMC Cancer. 2025;25:152.
PubMed Abstract available

TANG C, Sun SX, Gu C, Li CJ, et al
Diagnostic and prognostic values of tsRNAs in lung cancer: a meta-analysis.
BMC Cancer. 2025;25:153.
PubMed Abstract available

KUNCMAN L, Fijuth J, Tworek D, Sierko E, et al
Radiotherapy(R) Integration(I) Strategy for Small(S)-Cell Lung Cancer in Extensive(E) Stage (RISE) with up to 10 metastases- a study protocol of a randomized phase II trial.
BMC Cancer. 2025;25:142.
PubMed Abstract available

ZHOU Y, Zhao L, Cai M, Luo D, et al
Utilizing sc-linker to integrate single-cell RNA sequencing and human genetics to identify cell types and driver genes associated with non-small cell lung cancer.
BMC Cancer. 2025;25:130.
PubMed Abstract available

NI R, Huang Y, Wang L, Chen H, et al
An early lung cancer diagnosis model for non-smokers incorporating ct imaging analysis and circulating genetically abnormal cells (CACs).
BMC Cancer. 2025;25:124.
PubMed Abstract available

MA J, Xu X, Huang W, Hu Y, et al
Prognostic analysis of helical tomotherapy stereotactic body radiotherapy in multiple primary or second primary lung cancers.
BMC Cancer. 2025;25:118.
PubMed Abstract available

YANG H, Li MH, Li QH, Cheng KB, et al
Clinical analysis of pulmonary mucosa-associated lymphoid tissue lymphoma coexisting with lung cancer.
BMC Cancer. 2025;25:120.
PubMed Abstract available

SHIGENOBU T, Taniguchi Y, Suzuki T, Tabuchi Y, et al
Surgery versus concurrent chemoradiotherapy for stage III non-small cell lung cancer: a retrospective study with propensity score matching.
BMC Cancer. 2025;25:121.
PubMed Abstract available

CHEN S, Wu S
Ensemble machine learning models for lung cancer incidence risk prediction in the elderly: a retrospective longitudinal study.
BMC Cancer. 2025;25:126.
PubMed Abstract available

LIAO R, Yi G, Shen L, Xiao X, et al
Characterization of the genomic landscape in liver oligometastatic NSCLC.
BMC Cancer. 2025;25:93.
PubMed Abstract available

LIU X, Lv W, Huang D, Cui H, et al
The predictive role of tertiary lymphoid structures in the prognosis and response to immunotherapy of lung cancer patients: a systematic review and meta-analysis.
BMC Cancer. 2025;25:87.
PubMed Abstract available

ZHANG F, Qi F, Han Y, Yang H, et al
Clinical and imaging features of co-existent pulmonary tuberculosis and lung cancer: a population-based matching study in China.
BMC Cancer. 2025;25:89.
PubMed Abstract available

YANG M, Zheng G, Chen F, Tang H, et al
Molecular characterization of EBV-associated primary pulmonary lymphoepithelial carcinoma by multiomics analysis.
BMC Cancer. 2025;25:85.
PubMed Abstract available

YIN W, Lin Z, Gong WJ, Wang WX, et al
Smoking cessation is a protective factor for lung cancer onset and mortality: a population-based prospective cohort study.
BMC Cancer. 2025;25:86.
PubMed Abstract available

YING S, Wu N, Ruan Y, Ge W, et al
IL-17 triggers PD-L1 gene transcription in NSCLC cells via TRIM31-dependent MEF2C K63-linked polyubiquitination.
BMC Cancer. 2025;25:81.
PubMed Abstract available

LUAN Y, Liang C, Han Q, Zhou X, et al
The systematic analysis of genes related to butyrate metabolism suggests that CDKN3 could serve as a promising therapeutic target for lung adenocarcinoma treatment.
BMC Cancer. 2025;25:69.
PubMed Abstract available

WANG Z, Cui W, Liang L, Qu J, et al
Exploring the role of ELOVLs family in lung adenocarcinoma based on bioinformatic analysis and experimental validation.
BMC Cancer. 2025;25:62.
PubMed Abstract available

ZUO Z, Deng J, Ge W, Zhou Y, et al
Quantifying intratumoral heterogeneity within sub-regions to predict high-grade patterns in clinical stage I solid lung adenocarcinoma.
BMC Cancer. 2025;25:51.
PubMed Abstract available

ZHANG R, Jiang Y, Gu J, Zhang X, et al
Diagnostic role of circulating long non-coding RNA LINC00312 in patients with non-small cell lung cancer: a retrospective study.
BMC Cancer. 2025;25:47.
PubMed Abstract available

ZHAO Y, Zhou C, Zuo L, Yan H, et al
Identification of cancer cell-intrinsic biomarkers associated with tumor progression and characterization of SFTA3 as a tumor suppressor in lung adenocarcinomas.
BMC Cancer. 2025;25:36.
PubMed Abstract available

LISHCHUK P, Kuznietsova H, Dovbynchuk T, Dziubenko N, et al
Impact of irradiation conditions on therapy of Lewis lung carcinoma in mice using glucose-ethylenediamine carbon dots.
BMC Cancer. 2025;25:39.
PubMed Abstract available

EVERATT R, Kuzmickiene I, Brasiuniene B, Vincerzevskiene I, et al
Postdiagnostic use of antihypertensive medications and survival in colorectal, lung, corpus uteri, melanoma and kidney cancer patients with hypertension.
BMC Cancer. 2025;25:38.
PubMed Abstract available

XIONG Y, Ma Y, Lei J, Zhu J, et al
Highly proliferating cancer cells function as novel prognostic biomarkers for lung adenocarcinoma with particular usefulness for stage IA risk stratification.
BMC Cancer. 2025;25:25.
PubMed Abstract available

HAMAKAWA Y, Hirahara A, Hayashi A, Ito K, et al
Prognostic value of systemic immune-inflammation index in patients with small-cell lung cancer treated with immune checkpoint inhibitors.
BMC Cancer. 2025;25:17.
PubMed Abstract available

ZHU L, Liu J, Huang X, Hu J, et al
Preoperative immunochemotherapy versus chemotherapy as first-line treatment for patients with stage I-IIIB small-cell lung cancer.
BMC Cancer. 2025;25:8.
PubMed Abstract available

GONG W, Vaishnani DK, Jin XC, Zeng J, et al
Evaluation of an enhanced ResNet-18 classification model for rapid On-site diagnosis in respiratory cytology.
BMC Cancer. 2025;25:10.
PubMed Abstract available

LIAN Z, Liu X, Li X
Elucidating the expression and role of cGAS in pan-cancer using integrated bioinformatics and experimental approaches.
BMC Cancer. 2025;25:5.
PubMed Abstract available

December 2024

LUAN T, Hao J, Gu Y, He P, et al
A clinical analysis and literature review of eleven cases with primary pulmonary angiosarcoma.
BMC Cancer. 2024;24:1597.
PubMed Abstract available

BORILOVA S, Grell P, Selingerova I, Gescheidtova L, et al
Early changes of peripheral circulating immune subsets induced by PD-1 inhibitors in patients with advanced malignant melanoma and non-small cell lung cancer.
BMC Cancer. 2024;24:1590.
PubMed Abstract available

WANG B, Zhang J, Shi Y, Wang Y, et al
Clinical significance of the combined systemic immune-inflammatory index and prognostic nutritional index in predicting the prognosis of patients with extensive-stage small-cell lung cancer receiving immune-combination chemotherapy.
BMC Cancer. 2024;24:1574.
PubMed Abstract available

DENG G, Zhang Q, Fan J, Zhao C, et al
Optimal intervention timing for craniocerebral radiotherapy in EGFR mutant lung adenocarcinoma patients with brain metastases.
BMC Cancer. 2024;24:1571.
PubMed Abstract available

LIU Y, Geng Q, Lin X, Feng C, et al
Benefits, harms, and cost-effectiveness of risk model-based and risk factor-based low-dose computed tomography screening strategies for lung cancer: a systematic review.
BMC Cancer. 2024;24:1567.
PubMed Abstract available

MA F, Zheng W, Wang W, Zhang N, et al
The mediating role of medical coping modes between stigma and quality of life in patients undergoing lung cancer surgery: a cross-sectional study.
BMC Cancer. 2024;24:1561.
PubMed Abstract available

LOCQUET M, Jacob S, Geets X, Beaudart C, et al
Dose-volume predictors of cardiac adverse events after high-dose thoracic radiation therapy for lung cancer: a systematic review and meta-analysis.
BMC Cancer. 2024;24:1556.
PubMed Abstract available

XIE X, Li Y, Lv Q, Wang W, et al
Immune-related adverse events correlate with the clinical efficacy in advanced Non-Small-Cell Lung Cancer patients treated with PD-1 inhibitors combination therapy.
BMC Cancer. 2024;24:1541.
PubMed Abstract available

JIANG D, Wang Z, Li H, Liu J, et al
Experiences of patient delay among lung cancer patients in South China.
BMC Cancer. 2024;24:1527.
PubMed Abstract available

ZHANG W, Dai T, Wang D, Zhu Y, et al
Efficacy of neoadjuvant PD-1/PD-L1 inhibitor in resectable NSCLC: a meta-analysis based on randomized controlled trials.
BMC Cancer. 2024;24:1522.
PubMed Abstract available

ZHANG Y, Zeng Y, Yin Y, Zhang W, et al
The role of radiotherapy in extensive-stage small cell lung cancer: insights from treatment failure patterns in the era of immunotherapy.
BMC Cancer. 2024;24:1534.
PubMed Abstract available

MOU K, Wang H, Zhu S, Luo J, et al
Comprehensive analysis of the prognostic and immunological role of cavins in non-small cell lung cancer.
BMC Cancer. 2024;24:1525.
PubMed Abstract available

SONG J, Ye X, Peng Q, Ying X, et al
Correction: Circulating Tumor cells and multiple indicators combined to identify the risk of poorer prognosis in patients with resected non-small cell lung cancer.
BMC Cancer. 2024;24:1511.
PubMed

ZHENG X, Liu K, Gao Z, Li C, et al
Predicting overall survival and prophylactic cranial irradiation benefit in small cell lung cancer patients: a multicenter cohort study.
BMC Cancer. 2024;24:1507.
PubMed Abstract available

CHEN Q, Li Y, Lin Y, Lin X, et al
Effectiveness of non-pharmacological interventions in managing symptom clusters among lung cancer patients: a systematic review.
BMC Cancer. 2024;24:1505.
PubMed Abstract available

ZHANG X, Sun Q, Chen R, Zhao M, et al
Efficacy and safety of combining anti-angiogenic therapy, radiotherapy, and PD-1 inhibitors in patients with driver gene-negative non-small cell lung cancer brain metastases: a retrospective study.
BMC Cancer. 2024;24:1492.
PubMed Abstract available

SONG J, Ye X, Peng Q, Ying X, et al
Circulating Tumor cells and multiple indicators combined to identify the risk of poorer prognosis in patients with resected non-small cell lung cancer.
BMC Cancer. 2024;24:1491.
PubMed Abstract available

November 2024

SON JW, Lee J, Jeon JH, Cho S, et al
Validation of IASLC 9th edition TNM classification for lung cancer: focus on N descriptor.
BMC Cancer. 2024;24:1460.
PubMed Abstract available

DEHGHANI F, Toorang F, Seyyedsalehi MS, Sasanfar B, et al
Association between the dietary inflammatory index and risk of lung cancer: a multi-centered case-control study.
BMC Cancer. 2024;24:1452.
PubMed Abstract available

LEI S, Tian L, Yang L, Yang Y, et al
Efficacy and safety of RET-TKI in advanced RET-rearranged non-small cell lung cancer in China: a real-world retrospective chart review.
BMC Cancer. 2024;24:1427.
PubMed Abstract available

KOYAMA J, Morise M, Furukawa T, Oyama S, et al
Artificial intelligence-based personalized survival prediction using clinical and radiomics features in patients with advanced non-small cell lung cancer.
BMC Cancer. 2024;24:1417.
PubMed Abstract available

RASMUSSEN TR, Gouliaev A, Jakobsen E, Hjorthaug K, et al
Impact of multidisciplinary team discrepancies on comparative lung cancer outcome analyses and treatment equality.
BMC Cancer. 2024;24:1423.
PubMed Abstract available

BADE BC, Gan G, Li F, Lu L, et al
Correction: Randomized trial of physical activity on quality of life and lung cancer biomarkers in patients with advanced stage lung cancer: a pilot study.
BMC Cancer. 2024;24:1409.
PubMed

ZHANG X, Meng J, Gao M, Gong C, et al
Identifying immunohistochemical biomarkers panel for non-small cell lung cancer in optimizing treatment and forecasting efficacy.
BMC Cancer. 2024;24:1397.
PubMed Abstract available

LIU A, Wang X, Wang L, Zhuang H, et al
EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR-mutated NSCLC: a network meta-analysis.
BMC Cancer. 2024;24:1390.
PubMed Abstract available

LI Y, Shi D, Jiang Y, Hu Y, et al
Establishment of potential lncRNA-related hub genes involved competitive endogenous RNA in lung adenocarcinoma.
BMC Cancer. 2024;24:1371.
PubMed Abstract available

MAO Y, Chen F, Ye Z, Li Z, et al
Neoadjuvant immune checkpoint inhibitor reduced recurrence in operable NSCLC patients with pathological complete response: a retrospective analysis.
BMC Cancer. 2024;24:1366.
PubMed Abstract available

ZHANG Y, Li J, Song X, Zhao F, et al
Determining optimal clinical target volume margins based on microscopic extracapsular extension of metastatic nodes in patients with non-small-cell lung cancer after chemotherapy or chemotherapy combined with immunotherapy.
BMC Cancer. 2024;24:1368.
PubMed Abstract available

CHEN Z, Yi G, Li X, Yi B, et al
Predicting radiation pneumonitis in lung cancer using machine learning and multimodal features: a systematic review and meta-analysis of diagnostic accuracy.
BMC Cancer. 2024;24:1355.
PubMed Abstract available

ZAFAR A, Rashid AA, Moeed A, Tahir MJ, et al
Safety and efficacy of PD-1/PD-L1 immune checkpoint inhibitors in patients with pre-treated advanced stage malignant mesothelioma: a systematic review and meta-analysis.
BMC Cancer. 2024;24:1353.
PubMed Abstract available

JI Y, Harris MA, Newton LM, Harris TJ, et al
Osteosarcoma cells depend on MCL-1 for survival, and osteosarcoma metastases respond to MCL-1 antagonism plus regorafenib in vivo.
BMC Cancer. 2024;24:1350.
PubMed Abstract available

TANG J, Wang T, Wu H, Bao X, et al
Efficacy and toxicity of lurbinectedin in subsequent systemic therapy of extensive-stage small cell lung cancer: a meta-analysis.
BMC Cancer. 2024;24:1351.
PubMed Abstract available

October 2024

WANG T, Li R, Liu S, Wu Q, et al
The effects of immune checkpoint inhibitors vs. chemotherapy combined with brain radiotherapy in non-small cell lung cancer patients with brain metastases.
BMC Cancer. 2024;24:1343.
PubMed Abstract available

SESTER S, Wilms G, Ahlburg J, Babendreyer A, et al
Elevated expression levels of the protein kinase DYRK1B induce mesenchymal features in A549 lung cancer cells.
BMC Cancer. 2024;24:1341.
PubMed Abstract available

XIONG Y, Wang L, Zhang W, Meng Y, et al
First-line treatment with gefitinib in combination with bevacizumab and chemotherapy in advanced non-squamous NSCLC with EGFR-mutation.
BMC Cancer. 2024;24:1326.
PubMed Abstract available

WU DN, Zhang KL, Chen RH, Ye WS, et al
VASN promotes the aggressive phenotype in ARID1A-deficient lung adenocarcinoma.
BMC Cancer. 2024;24:1327.
PubMed Abstract available

TANG Y, Zhao S, Zhou L, Huang Y, et al
A 16-year evaluation of opportunistic lung cancer screening with low-dose CT in China: comparative findings between non-smokers and smokers.
BMC Cancer. 2024;24:1322.
PubMed Abstract available

SHEN F, Wu X, Geng J, Guo W, et al
Prognostic factors for resected invasive mucinous lung adenocarcinoma: a systematic review and meta-analysis.
BMC Cancer. 2024;24:1317.
PubMed Abstract available

SANTORO A, Pilar G, Tan DSW, Zugazagoitia J, et al
Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC.
BMC Cancer. 2024;24:1307.
PubMed Abstract available

TONG Y, Wan X, Yin C, Lei T, et al
In-depth exploration of the focus issues of TKI combined with radiotherapy for EGFR-mutant lung adenocarcinoma patients with brain metastasis: a systematic analysis based on literature metrology, meta-analysis, and real-world observational data.
BMC Cancer. 2024;24:1305.
PubMed Abstract available

MENG F, Ren N, Zhang G, Xu R, et al
Comprehensive analysis of surgical strategies and prognosis for non-small cell lung cancer with pleural metastasis detected intraoperatively.
BMC Cancer. 2024;24:1303.
PubMed Abstract available

SAITO Y, Takekuma Y, Sakakibara-Konishi J, Shimizu Y, et al
Effect of baseline anemia on the efficacy of docetaxel and ramucirumab for advanced non-small cell lung cancer treatment.
BMC Cancer. 2024;24:1301.
PubMed Abstract available

SUGAI K, Mori T, Bilal T, Furukawa A, et al
Detection of circulating tumor cells in patients with lung cancer using a rare cell sorter: a pilot study.
BMC Cancer. 2024;24:1291.
PubMed Abstract available

WANG F, Liu J, Liao W, Zheng L, et al
Matrine alkaloids modulating DNA damage repair in chemoresistant non-small cell lung cancer cells.
BMC Cancer. 2024;24:1283.
PubMed Abstract available

YU Q, Yang H, Xiao F, Wang Z, et al
Network meta-analysis on the efficacy and safety of management for resectable stage IIIA-N2 non-small cell lung cancer.
BMC Cancer. 2024;24:1286.
PubMed Abstract available

DING D, Shang W, Shi K, Ying J, et al
FTO/m6A mediates miR-138-5p maturation and regulates gefitinib resistance of lung adenocarcinoma cells by miR-138-5p/LCN2 axis.
BMC Cancer. 2024;24:1270.
PubMed Abstract available

HEMEAD H, Aly RG, Kotb M, Abdelaziz A, et al
Pediatric pleuropulmonary blastoma: analysis of four cases.
BMC Cancer. 2024;24:1268.
PubMed Abstract available

HOU Q, Liang Y, Yao N, Liu J, et al
Development of a novel nomogram for patients with SCLC and comparison with other models.
BMC Cancer. 2024;24:1257.
PubMed Abstract available

SHEN Z, Huang Z, Zhu T, Zhang J, et al
Optimal surgical timing for lung cancer following SARS-CoV-2 infection: a prospective multicenter cohort study.
BMC Cancer. 2024;24:1250.
PubMed Abstract available

CHENG H, Wang X, Yao J, Guo N, et al
Assessing the causal relationship between non-small cell lung cancer and sepsis: a Mendelian randomization study.
BMC Cancer. 2024;24:1233.
PubMed Abstract available

ZHANG L, Wang S, Wang L
Comprehensive analysis identifies YKT6 as a potential prognostic and diagnostic biomarker in lung adenocarcinoma.
BMC Cancer. 2024;24:1235.
PubMed Abstract available

WU D, Li Y, Zhou M, Gong F, et al
Deep learning-based characterization of pathological subtypes in lung invasive adenocarcinoma utilizing (18)F-deoxyglucose positron emission tomography imaging.
BMC Cancer. 2024;24:1229.
PubMed Abstract available

ZHU X, Shen C, Dong J
A clinically applicable model more suitable for predicting malignancy or benignity of pulmonary ground glass nodules in women patients.
BMC Cancer. 2024;24:1225.
PubMed Abstract available

YILMAZ F, Yasar S, Tatar OD, Yildirim HC, et al
Bi-weekly irinotecan is an effective and convenient regimen in the treatment of relapsed or refractory small cell lung cancer.
BMC Cancer. 2024;24:1218.
PubMed Abstract available

September 2024

SUN M, Ji H, Deng F, Li J, et al
Clinical outcomes and synergistic effect between radiotherapy and immunotherapy in patients with extensive-stage small cell lung cancer: a real-world study.
BMC Cancer. 2024;24:1206.
PubMed Abstract available

BOZCUK HS, Artac M
A simulated trial with reinforcement learning for the efficacy of Irinotecan and Ifosfamide versus Topotecan in relapsed, extensive stage small cell lung cancer.
BMC Cancer. 2024;24:1207.
PubMed Abstract available

DING W, Xu T, Xiang H, Liang J, et al
Is clinical target volume necessary for locally advanced non-small cell lung cancer treated with 4D-CT intensity-modulated radiation therapy.
BMC Cancer. 2024;24:1198.
PubMed Abstract available

LI H, Fu X, Liu M, Chen J, et al
Novel prediction model of early screening lung adenocarcinoma with pulmonary fibrosis based on haematological index.
BMC Cancer. 2024;24:1178.
PubMed Abstract available

WANG W, Wu G, Luo W, Lin L, et al
Anlotinib plus oral fluoropyrimidine S-1 in refractory or relapsed small-cell lung cancer (SALTER TRIAL): a multicenter, single-arm, phase II trial.
BMC Cancer. 2024;24:1182.
PubMed Abstract available

DENG JY, Yang MY, Yang XR, Chen ZH, et al
Patterns of failure and the subsequent treatment after progression on first-line immunotherapy monotherapy in advanced non-small cell lung cancer: a retrospective study.
BMC Cancer. 2024;24:1190.
PubMed Abstract available

TOORANG F, Seyyedsalehi MS, Sasanfar B, Rashidian H, et al
Dietary total antioxidant capacity and odds of lung cancer: a large case-control study.
BMC Cancer. 2024;24:1196.
PubMed Abstract available

HUSSEIN NA, Ebied SA, Belal AAM, Ahmad MA, et al
Expression profiling of circulating lncRNA GIAT4RA, lncRNA AATBC, lncRNA Sirt1-AS, and SMARCB1 in lung cancer patients.
BMC Cancer. 2024;24:1175.
PubMed Abstract available

DENG Y, Chen X, Chen X, Huang C, et al
UBE2T promotes stage I lung adenocarcinoma progression through PBX1 ubiquitination and PBX1/RORA regulation.
BMC Cancer. 2024;24:1158.
PubMed Abstract available

XU S, Chen X, Ying H, Chen J, et al
Multi?omics identification of a signature based on malignant cell-associated ligand-receptor genes for lung adenocarcinoma.
BMC Cancer. 2024;24:1138.
PubMed Abstract available

CUI J, An Z, Zhou X, Zhang X, et al
Prognosis and risk factor assessment of patients with advanced lung cancer with low socioeconomic status: model development and validation.
BMC Cancer. 2024;24:1128.
PubMed Abstract available

LIU R, Wang J, Zhang L, Wang S, et al
GLIDR-mediated regulation of tumor malignancy and cisplatin resistance in non-small cell lung cancer via the miR-342-5p/PPARGC1A axis.
BMC Cancer. 2024;24:1126.
PubMed Abstract available

RUCO A, Lofters AK, Lu H, Baxter NN, et al
Lung cancer survival by immigrant status: a population-based retrospective cohort study in Ontario, Canada.
BMC Cancer. 2024;24:1114.
PubMed Abstract available

HAGHIGHIKIAN SM, Shirinzadeh-Dastgiri A, Ershadi R, Vakili-Ojarood M, et al
Correlation of TNF-alpha polymorphisms with susceptibility to lung cancer: evidence from a meta-analysis based on 29 studies.
BMC Cancer. 2024;24:1113.
PubMed Abstract available

WANG W, Zhang X, Gui P, Zou Q, et al
SEPT9: From pan-cancer to lung squamous cell carcinoma.
BMC Cancer. 2024;24:1105.
PubMed Abstract available

YANG D, Yang Y, Zhao M, Ji H, et al
Evaluation of the invasiveness of pure ground-glass nodules based on dual-head ResNet technique.
BMC Cancer. 2024;24:1080.
PubMed Abstract available

BEFFA ED, Lyberis P, Rosboch GL, Arezzo A, et al
Study protocol for Near-infrared molecular imaging for lung cancer detection and treatment during mini-invasive surgery (phase II Trial) - (the RECOGNISE study).
BMC Cancer. 2024;24:1078.
PubMed Abstract available

August 2024

XU S, Zheng Y, Ye M, Shen T, et al
Comprehensive pan-cancer analysis reveals EPHB2 is a novel predictive biomarker for prognosis and immunotherapy response.
BMC Cancer. 2024;24:1064.
PubMed Abstract available

LI Q, Liang N, Ouyang W, Su S, et al
Appropriate delay of primary tumour radiotherapy may lead to better long-term overall survival for non-small cell lung cancer treated with EGFR-TKIs.
BMC Cancer. 2024;24:1053.
PubMed Abstract available

SHI Y, Xu Y, Wang M
Current clinical practice and physicians' insights on Chinese patients with advanced non-small cell lung cancer habouring epidermal growth factor receptor 20 insertion mutation.
BMC Cancer. 2024;24:1043.
PubMed Abstract available

HOSOYA K, Ozasa H, Tanji M, Yoshida H, et al
Performance status improvement and advances in systemic treatment after brain metastases resection: a retrospective single-center cohort study of non-small cell lung cancer patients.
BMC Cancer. 2024;24:1030.
PubMed Abstract available

LUO LL, Cao Y, Zhang JJ, Xie YX, et al
The role of tRF-Val-CAC-010 in lung adenocarcinoma: implications for tumorigenesis and metastasis.
BMC Cancer. 2024;24:1033.
PubMed Abstract available

WU W, Yu S, Huang J, Qi Q, et al
Molecular heterogeneity and treatment outcome of EGFR exon 20 insertion mutations in Chinese patients with advanced non-small cell lung cancer: insights from a large-scale real-world study.
BMC Cancer. 2024;24:1010.
PubMed Abstract available

SHAN H, Wang X, Yin F, Zhou Y, et al
Combination of transcriptome and Mendelian inheritance reveals novel prognostic biomarker of CTLA-4-related lncRNAs and protective role of nitrogen metabolism pathway in lung adenocarcinoma development.
BMC Cancer. 2024;24:1009.
PubMed Abstract available

PARK JO, Feng YH, Su WC, Oh DY, et al
Erdafitinib in Asian patients with advanced solid tumors: an open-label, single-arm, phase IIa trial.
BMC Cancer. 2024;24:1006.
PubMed Abstract available

AHSAN S, Win TT, Aye SN, Than NN, et al
The role of circular RNAs (circRNAs) as a prognostic factor in lung cancer: a meta-analysis.
BMC Cancer. 2024;24:988.
PubMed Abstract available

SUN V, Guthrie KA, Arnold KB, Antonoff M, et al
Comparative effectiveness of perioperative physical activity in older adults with lung cancer and their family caregivers: design of a multicenter pragmatic randomized trial.
BMC Cancer. 2024;24:976.
PubMed Abstract available

MA Z, Liu Y, Bao Y, Liu Q, et al
Higher immune cell radiation dose is correlated with poor tumor control and survival in patients with non-small cell lung cancer receiving postoperative radiotherapy.
BMC Cancer. 2024;24:968.
PubMed Abstract available

ZHANG J, Lv PY, Zhao X, Liu ML, et al
Real-world effectiveness and safety of recombinant human endostatin plus PD-1 inhibitors and chemotherapy as first-line treatment for EGFR/ALK-negative, advanced or metastatic non-small cell lung cancer.
BMC Cancer. 2024;24:967.
PubMed Abstract available

KENNEDY K, Jusue-Torres I, Buller ID, Rossi E, et al
Neighborhood-level deprivation and survival in lung cancer.
BMC Cancer. 2024;24:959.
PubMed Abstract available

AKDOGAN O, Ogut B, Sutcuoglu O, Sert A, et al
The impact of the expression level of growth differentiation factor 15 in tumor tissue on the response to immunotherapy in non-small cell lung cancer.
BMC Cancer. 2024;24:954.
PubMed Abstract available

YAO N, Qin Z, Chen M, Hu L, et al
Effects of brain radiotherapy strategies on survival in the era of MRI for patients with limited stage small cell lung cancer.
BMC Cancer. 2024;24:953.
PubMed Abstract available

GARRIDO J, Bernal Y, Gonzalez E, Blanco A, et al
Beyond tobacco: genomic disparities in lung cancer between smokers and never-smokers.
BMC Cancer. 2024;24:951.
PubMed Abstract available

QIN H, Yan H, Chen Y, Xu Q, et al
Clinical outcomes for immune checkpoint inhibitors plus chemotherapy in non-small-cell lung cancer patients with uncommon driver gene alterations.
BMC Cancer. 2024;24:952.
PubMed Abstract available

LAHMADI M, Beddar L, Ketit S, Makhbouche T, et al
Clinicopathological characteristics and prognosis of non-small cell lung cancer in Algeria: a single-center retrospective study.
BMC Cancer. 2024;24:946.
PubMed Abstract available

DENG H, Wang L, Li Z, Zhan T, et al
Optimal treatment strategies for hepatoid adenocarcinoma of the lung: insights from a comprehensive analysis.
BMC Cancer. 2024;24:948.
PubMed Abstract available

MCINNERNEY D, Quaife SL, Cooke S, Mitchinson L, et al
Understanding the impact of distance and disadvantage on lung cancer care and outcomes: a study protocol.
BMC Cancer. 2024;24:942.
PubMed Abstract available

CHEN F, Ren P, Xu R, Zhang J, et al
FAM65A promotes the progression and growth of lung squamous cell carcinoma in vivo and vitro.
BMC Cancer. 2024;24:944.
PubMed Abstract available

KASEDA K, Asakura K, Shintani Y, Okami J, et al
Surgically resected sarcomatoid carcinoma of the lung: a nationwide retrospective study in 2010.
BMC Cancer. 2024;24:938.
PubMed Abstract available

FRAK M, Grenda A, Krawczyk P, Kuznar-Kaminska B, et al
The influence of nutritional status, lipid profile, leptin concentration and polymorphism of genes encoding leptin and neuropeptide Y on the effectiveness of immunotherapy in advanced NSCLC patients.
BMC Cancer. 2024;24:937.
PubMed Abstract available

July 2024

GE QY, Zheng C, Zhang GC, Cong ZZ, et al
Establishment and verification of novel TNM staging system for lung mucinous adenocarcinoma.
BMC Cancer. 2024;24:925.
PubMed Abstract available

LI Z, Wang J, Deng L, Zhai Y, et al
Hippocampal avoidance whole-brain radiotherapy with simultaneous integrated boost in lung cancer brain metastases and utility of the Hopkins verbal learning test for testing cognitive impairment in Chinese patients: a prospective phase II study.
BMC Cancer. 2024;24:899.
PubMed Abstract available

TOKITO T, Kolesnik O, Sorensen J, Artac M, et al
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab as first-line treatment for metastatic non-small cell lung cancer with high levels of programmed death-ligand 1: a randomized, double-blind phase 2 study.
BMC Cancer. 2024;23.
PubMed Abstract available

BOYER M, Hui R, Urban D, Clingan P, et al
Pembrolizumab with platinum-based chemotherapy with or without epacadostat as first-line treatment for metastatic non-small cell lung cancer: a randomized, partially double-blind, placebo-controlled phase II study.
BMC Cancer. 2024;23.
PubMed Abstract available

WEN Y, Wu W, Liufu Y, Pan X, et al
Differentiation of granulomatous nodules with lobulation and spiculation signs from solid lung adenocarcinomas using a CT deep learning model.
BMC Cancer. 2024;24:875.
PubMed Abstract available

YAN W, Yang H, Duan D, Wu Y, et al
Bone marrow mesenchymal stem cells-derived exosomal miR-145-5p reduced non-small cell lung cancer cell progression by targeting SOX9.
BMC Cancer. 2024;24:883.
PubMed Abstract available

HUI W, Gao Z, Zhu M, Wu H, et al
Reply to "Matters arising: cost-effectiveness of first-line immunotherapy combinations with or without chemotherapy for advanced non-small cell lung cancer: a modelling approach".
BMC Cancer. 2024;24:881.
PubMed Abstract available

LEARY A, Estevez-Garcia P, Sabatier R, Ray-Coquard I, et al
ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer.
BMC Cancer. 2024;24:876.
PubMed Abstract available

BULLEMENT A, Edmondson-Jones M, Latimer N
Cost-effectiveness of first-line immunotherapy combinations with or without chemotherapy for advanced non-small cell lung cancer: a modelling approach.
BMC Cancer. 2024;24:879.
PubMed

WANG Y, Chen R, Guo Z, Wei W, et al
Immunological profiling for short-term predictive analysis in PD-1/PD-L1 therapy for lung cancer.
BMC Cancer. 2024;24:851.
PubMed Abstract available

WU G, Liu J, Shi H, Pan B, et al
The associations between dysregulation of human blood metabolites and lung cancer risk: evidence from genetic data.
BMC Cancer. 2024;24:854.
PubMed Abstract available

CHEN Y, Wu S, Han Y, Shi H, et al
LncRNA SH3PXD2A-AS1 facilitates cisplatin resistance in non-small cell lung cancer by regulating FOXM1 succinylation.
BMC Cancer. 2024;24:848.
PubMed Abstract available

YAMAGUCHI T, Shimizu J, Matsuzawa R, Watanabe N, et al
Efficacy of chemotherapy plus immune checkpoint inhibitors in patients with non-small cell lung cancer who have rare oncogenic driver mutations: a retrospective analysis.
BMC Cancer. 2024;24:842.
PubMed Abstract available

BIAN Y, Liu H, Huang J, Feng Z, et al
eHSP90alpha in front-line therapy in EGFR exon 19 deletion and 21 Leu858Arg mutations in advanced lung adenocarcinoma.
BMC Cancer. 2024;24:835.
PubMed Abstract available

MA L, Li R, Liu X, Yu W, et al
Prognostic and clinicopathological significance of tertiary lymphoid structure in non-small cell lung cancer: a systematic review and meta-analysis.
BMC Cancer. 2024;24:815.
PubMed Abstract available

LIN P, Zhang L, Tang X, Wang J, et al
Exploring the causal association between uric acid and lung cancer in east Asian and European populations: a mendelian randomization study.
BMC Cancer. 2024;24:801.
PubMed Abstract available

YAN L, Su H, Liu J, Wen X, et al
Rapid detection of lung cancer based on serum Raman spectroscopy and a support vector machine: a case-control study.
BMC Cancer. 2024;24:791.
PubMed Abstract available

June 2024

CHENG Y, Zhang C, Li Q, Yang X, et al
MTF1 genetic variants are associated with lung cancer risk in the Chinese Han population.
BMC Cancer. 2024;24:778.
PubMed Abstract available

FAN X, Zhong R, Liang H, Zhong Q, et al
Exhaled VOC detection in lung cancer screening: a comprehensive meta-analysis.
BMC Cancer. 2024;24:775.
PubMed Abstract available

XIAO X, Sun Z, Liang S, Li W, et al
Liquid-based cytology specimens for next-generation sequencing in lung adenocarcinoma: challenges and evaluation of targeted therapy.
BMC Cancer. 2024;24:749.
PubMed Abstract available

ZHANG B, Liu H, Shi C, Gao Z, et al
Safety and efficacy of multi-target TKI combined with nivolumab in check-point inhibitor-refractory patients with advanced NSCLC: a prospective, single-arm, two-stage study.
BMC Cancer. 2024;24:715.
PubMed Abstract available

SONG L, Wu D, Wu J, Zhang J, et al
Investigating causal associations between pneumonia and lung cancer using a bidirectional mendelian randomization framework.
BMC Cancer. 2024;24:721.
PubMed Abstract available

HUI W, Li W, Song R, Xin Y, et al
Time-dependent efficacy analysis of first-line immunotherapies for advanced non-small cell lung cancer.
BMC Cancer. 2024;24:684.
PubMed Abstract available

LIU Y, Huang J, Chen JC, Chen W, et al
Predicting treatment response in multicenter non-small cell lung cancer patients based on federated learning.
BMC Cancer. 2024;24:688.
PubMed Abstract available

BIYU H, Mengshan L, Yuxin H, Ming Z, et al
A miRNA-disease association prediction model based on tree-path global feature extraction and fully connected artificial neural network with multi-head self-attention mechanism.
BMC Cancer. 2024;24:683.
PubMed Abstract available

ZHAO J, Lu Y, Ren X, Bian T, et al
Association of the SHOX2 and RASSF1A methylation levels with the pathological evolution of early-stage lung adenocarcinoma.
BMC Cancer. 2024;24:687.
PubMed Abstract available

SONG W, Li Y, Yao Y, Sun S, et al
Systematic druggable genome-wide Mendelian randomization identifies therapeutic targets for lung cancer.
BMC Cancer. 2024;24:680.
PubMed Abstract available

YANG L, Jiang Z, Tong J, Li N, et al
Development and validation of a preoperative CT?based radiomics nomogram to differentiate tuberculosis granulomas from lung adenocarcinomas: an external validation study.
BMC Cancer. 2024;24:670.
PubMed Abstract available

May 2024

LU F, Wang E, Liu H
Factors correlating the expression of PD-L1.
BMC Cancer. 2024;24:642.
PubMed Abstract available

ZHAO W, Liu Y, Yang Y, Wang L, et al
New link between RNH1 and E2F1: regulates the development of lung adenocarcinoma.
BMC Cancer. 2024;24:635.
PubMed Abstract available

HAYASHI Y, Ueyama A, Funaki S, Jinushi K, et al
In situ analysis of CCR8(+) regulatory T cells in lung cancer: suppression of GzmB(+) CD8(+) T cells and prognostic marker implications.
BMC Cancer. 2024;24:627.
PubMed Abstract available

LI W, Wu J, Jia Q, Shi Y, et al
PD-L1 knockdown suppresses vasculogenic mimicry of non-small cell lung cancer by modulating ZEB1-triggered EMT.
BMC Cancer. 2024;24:633.
PubMed Abstract available

LIN X, Wang F, Li Y, Lei F, et al
Exploring shared decision-making needs in lung cancer screening among high-risk groups and health care providers in China: a qualitative study.
BMC Cancer. 2024;24:613.
PubMed Abstract available

PRETE M, Ballarin G, Porciello G, Arianna A, et al
Bioelectrical impedance analysis-derived phase angle (PhA) in lung cancer patients: a systematic review.
BMC Cancer. 2024;24:608.
PubMed Abstract available

LIAO S, Wang Y, Zhou J, Liu Y, et al
Associations between chronic obstructive pulmonary disease and ten common cancers: novel insights from Mendelian randomization analyses.
BMC Cancer. 2024;24:601.
PubMed Abstract available

PANG H, Dai L, Chen L, Chen X, et al
Prognostic value of the advanced lung cancer inflammation index in patients with gastric cancer after radical gastrectomy: a propensity-score matching cohort study and meta-analysis.
BMC Cancer. 2024;24:583.
PubMed Abstract available

GU C, Teng X, Sun X, Liu J, et al
Impact of treatment interval between neoadjuvant immunochemotherapy and surgery in lung squamous cell carcinoma.
BMC Cancer. 2024;24:585.
PubMed Abstract available

WANG M, Jing X, Chen F, Lu S, et al
Immune checkpoint inhibitor (ICI)-based treatment beyond progression with prior immunotherapy in patients with driver-gene negative advanced non-small cell lung cancer.
BMC Cancer. 2024;24:569.
PubMed Abstract available

XIA L, Lin H, Cao H, Lian J, et al
Tenascin C as a novel zinc finger protein 750 target regulating the immunogenicity via DNA damage in lung squamous cell carcinoma.
BMC Cancer. 2024;24:561.
PubMed Abstract available

April 2024

CUNNINGHAM R, Stanley J, Imlach F, Haitana T, et al
Cancer diagnosis after emergency presentations in people with mental health and substance use conditions: a national cohort study.
BMC Cancer. 2024;24:546.
PubMed Abstract available

VIANA VELOSO GG, Amaral FD, Nogueira-Rodrigues A
Impact of COVID-19 pandemic among patients with lung and head and neck cancer assisted in a public cancer center in Brazil.
BMC Cancer. 2024;24:539.
PubMed Abstract available

DENG Z, Liu X, Wu R, Yan H, et al
Ultrasound-based radiomics machine learning models for diagnosing cervical lymph node metastasis in patients with non-small cell lung cancer: a multicentre study.
BMC Cancer. 2024;24:536.
PubMed Abstract available

LI Y, Gong B, Guo Y, Liu W, et al
Non-small cell lung cancer and immune checkpoint inhibitor therapy: does non-alcoholic fatty liver disease have an effect?
BMC Cancer. 2024;24:535.
PubMed Abstract available

GUO Y, Pan Y, Wan J, Gong B, et al
Prognosis stratification of cancer patients treated with immune checkpoint inhibitors through lung immune prognostic index: a meta-analysis and systematic review.
BMC Cancer. 2024;24:523.
PubMed Abstract available

OKAYAMA T, Suzuki K, Morishita S, Inoue J, et al
Correction: Pretreatment quality of life and survival in patients with lung cancer: a systematic review and meta-analysis.
BMC Cancer. 2024;24:529.
PubMed

SKURIKHIN E, Ermakova N, Zhukova M, Pan E, et al
Effects of reprogrammed splenic CD8(+) T-cells in vitro and in mice with spontaneous metastatic Lewis lung carcinoma.
BMC Cancer. 2024;24:522.
PubMed Abstract available

SHI MX, Ding X, Tang L, Cao WJ, et al
PROTAC EZH2 degrader-1 overcomes the resistance of podophyllotoxin derivatives in refractory small cell lung cancer with leptomeningeal metastasis.
BMC Cancer. 2024;24:504.
PubMed Abstract available

HE M, Jiang W, Li X, Liu H, et al
25-hydroxycholesterol promotes proliferation and metastasis of lung adenocarcinoma cells by regulating ERbeta/TNFRSF17 axis.
BMC Cancer. 2024;24:505.
PubMed Abstract available

OKAYAMA T, Suzuki K, Morishita S, Inoue J, et al
Pretreatment quality of life and survival in patients with lung cancer: a systematic review and meta-analysis.
BMC Cancer. 2024;24:495.
PubMed Abstract available

XU K, Lu W, Yu A, Wu H, et al
Effect of the STK11 mutation on therapeutic efficacy and prognosis in patients with non-small cell lung cancer: a comprehensive study based on meta-analyses and bioinformatics analyses.
BMC Cancer. 2024;24:491.
PubMed Abstract available

MIMURA C, Takamiya R, Fujimoto S, Fukui T, et al
Utility of bronchoscopically obtained frozen cytology pellets for next-generation sequencing.
BMC Cancer. 2024;24:489.
PubMed Abstract available

LI Y, Chen Z, Tian S, Han X, et al
Stereotactic ablative brachytherapy versus percutaneous microwave ablation as salvage treatments for lung oligometastasis from colorectal cancer.
BMC Cancer. 2024;24:481.
PubMed Abstract available

MIAO SN, Chai MQ, Liu XY, Wei CY, et al
Exercise accelerates recruitment of CD8(+) T cell to promotes anti-tumor immunity in lung cancer via epinephrine.
BMC Cancer. 2024;24:474.
PubMed Abstract available

WU JR, Chen VC, Fang YH, Hsieh CC, et al
The associates of anxiety among lung cancer patients: Dehydroepiandrosterone (DHEA) as a potential biomarker.
BMC Cancer. 2024;24:476.
PubMed Abstract available

ZHANG D, Liu H, Zhao F, Guo P, et al
Exploring the relationship between Treg-mediated risk in COPD and lung cancer through Mendelian randomization analysis and scRNA-seq data integration.
BMC Cancer. 2024;24:453.
PubMed Abstract available

HUANG Y, Chen D, Bai Y, Zhang Y, et al
ESCO2's oncogenic role in human tumors: a pan-cancer analysis and experimental validation.
BMC Cancer. 2024;24:452.
PubMed Abstract available

KONG C, Yin X, Zou J, Ma C, et al
The application of different machine learning models based on PET/CT images and EGFR in predicting brain metastasis of adenocarcinoma of the lung.
BMC Cancer. 2024;24:454.
PubMed Abstract available

ARIMURA K, Kammer M, Rahman SMJ, Sheau-Chiann C, et al
Elucidating the role of EPPK1 in lung adenocarcinoma development.
BMC Cancer. 2024;24:441.
PubMed Abstract available

YANG Y, Xu J, Wang W, Ma M, et al
A nomogram based on the quantitative and qualitative features of CT imaging for the prediction of the invasiveness of ground glass nodules in lung adenocarcinoma.
BMC Cancer. 2024;24:438.
PubMed Abstract available

JIANG H, Li B, Wu M, Wang Q, et al
Association of the Advanced Lung Cancer Inflammation Index (ALI) and Gustave Roussy Immune (GRIm) score with immune checkpoint inhibitor efficacy in patients with gastrointestinal and lung cancer.
BMC Cancer. 2024;24:428.
PubMed Abstract available

LI H, Li L, Liu Y, Deng Y, et al
Predictive value of CT and (18)F-FDG PET/CT features on spread through air space in lung adenocarcinoma.
BMC Cancer. 2024;24:434.
PubMed Abstract available

CHEN M, Li R, Kong Y, Shi L, et al
Rational and design of prophylactic cranial irradiation (PCI) and brain MRI surveillance versus brain MRI surveillance alone in patients with limited-stage small cell lung cancer achieving complete remission (CR) of tumor after chemoradiotherapy: a mu
BMC Cancer. 2024;24:429.
PubMed Abstract available

DIVAN HA, Bittoni MA, Krishna A, Carbone DP, et al
Real-world patient characteristics and treatment patterns in US patients with advanced non-small cell lung cancer.
BMC Cancer. 2024;24:424.
PubMed Abstract available

MENNECIER B, Khalifa J, Descourt R, Greillier L, et al
Real-life clinical management patterns in extensive-stage small cell lung cancer across France: a multi-method study.
BMC Cancer. 2024;24:421.
PubMed Abstract available

BOUTABBA A, Missaoui F, Dlala A, Kamoun H, et al
Circulating miR-16-5p, miR-92a-3p and miR-451a are biomarkers of lung cancer in Tunisian patients.
BMC Cancer. 2024;24:417.
PubMed Abstract available

YANG F, Zheng Y, Luo Q, Zhang S, et al
Knockdown of NCAPD3 inhibits the tumorigenesis of non-small cell lung cancer by regulation of the PI3K/Akt pathway.
BMC Cancer. 2024;24:408.
PubMed Abstract available

SHENG M, Sun R, Fu J, Lu G, et al
The podoplanin-CLEC-2 interaction promotes platelet-mediated melanoma pulmonary metastasis.
BMC Cancer. 2024;24:399.
PubMed Abstract available

March 2024

ZENG A, Yin Y, Xu Z, Abuduwayiti A, et al
Down-regulated HHLA2 enhances neoadjuvant immunotherapy efficacy in patients with non-small cell lung cancer (NSCLC) with chronic obstructive pulmonary disease (COPD).
BMC Cancer. 2024;24:396.
PubMed Abstract available

WEI Q, Deng T, Wu J, Zeng H, et al
Immune checkpoint inhibitor plus chemotherapy as first-line treatment for non-small cell lung cancer with malignant pleural effusion: a retrospective multicenter study.
BMC Cancer. 2024;24:393.
PubMed Abstract available

ELBASHEER MMA, Bohrmann B, Chen Y, Lv J, et al
Reproductive factors and risk of lung cancer among 300,000 Chinese female never-smokers: evidence from the China Kadoorie Biobank study.
BMC Cancer. 2024;24:384.
PubMed Abstract available

XIE M, Gao J, Ma X, Song J, et al
The radiological characteristics, tertiary lymphoid structures, and survival status associated with EGFR mutation in patients with subsolid nodules like stage I-II LUAD.
BMC Cancer. 2024;24:372.
PubMed Abstract available

LI LX, Socinski MA, Kichenadasse G, Karapetis CS, et al
A lack of association between BMI and chemoimmunotherapy efficacy in advanced non-small cell lung cancer: Secondary analysis of the IMpower150 and IMpower130 clinical trials.
BMC Cancer. 2024;24:379.
PubMed Abstract available

QI H, Hou Y, Zheng Z, Zheng M, et al
Clinical characteristics and MRI based radiomics nomograms can predict iPFS and short-term efficacy of third-generation EGFR-TKI in EGFR-mutated lung adenocarcinoma with brain metastases.
BMC Cancer. 2024;24:362.
PubMed Abstract available

PAN J, Wang J, Tao W, Wang C, et al
Is low-dose computed tomography for lung cancer screening conveniently accessible in China? A spatial analysis based on cross-sectional survey.
BMC Cancer. 2024;24:342.
PubMed Abstract available

WANG S, Oliveira-Silveira J, Fang G, Kang J, et al
High-content analysis identified synergistic drug interactions between INK128, an mTOR inhibitor, and HDAC inhibitors in a non-small cell lung cancer cell line.
BMC Cancer. 2024;24:335.
PubMed Abstract available

KAHM YJ, Kim IG, Kim RK
Regulation of cancer stem cells by CXCL1, a chemokine whose secretion is controlled by MCM2.
BMC Cancer. 2024;24:319.
PubMed Abstract available

WU C, Cao B, He G, Li Y, et al
Stereotactic ablative brachytherapy versus percutaneous microwave ablation for early-stage non-small cell lung cancer: a multicenter retrospective study.
BMC Cancer. 2024;24:304.
PubMed Abstract available

CHENG M, Shao Y, Li L, Jiang M, et al
Cost-effectiveness of immunotherapies for advanced squamous non-small cell lung cancer: a systematic review.
BMC Cancer. 2024;24:312.
PubMed Abstract available

ZHOU J, Yu B, Guo P, Wang S, et al
The insufficiency of CT examination in early detection of central lung squamous cell carcinoma and squamous epithelial precancerous lesions.
BMC Cancer. 2024;24:299.
PubMed Abstract available

WANG Y, Ouyang S, Liu M, Si Q, et al
Humoral immune response to tumor-associated antigen Ubiquilin 1 (UBQLN1) and its tumor-promoting potential in lung cancer.
BMC Cancer. 2024;24:283.
PubMed Abstract available

LIU J, Bian T, She B, Liu L, et al
Evaluating the comprehensive diagnosis efficiency of lung cancer, including measurement of SHOX2 and RASSF1A gene methylation.
BMC Cancer. 2024;24:282.
PubMed Abstract available

February 2024

XU M, Li C, Xiang L, Chen S, et al
Assessing the causal relationship between 731 immunophenotypes and the risk of lung cancer: a bidirectional mendelian randomization study.
BMC Cancer. 2024;24:270.
PubMed Abstract available

WANG X, Zhao J, Mei T, Liu W, et al
Quantification of preexisting lung ground glass opacities on CT for predicting checkpoint inhibitor pneumonitis in advanced non-small cell lung cancer patients.
BMC Cancer. 2024;24:269.
PubMed Abstract available

CHEN K, Li S, Chen M, Jin Z, et al
Endostar acts as a pneumonitis protectant in patients with locally advanced non-small cell lung cancer receiving concurrent chemoradiotherapy.
BMC Cancer. 2024;24:257.
PubMed Abstract available

CHEN HC, Kuo CY, Chang Y, Tsai DL, et al
5-Methoxytryptophan enhances the sensitivity of sorafenib on the inhibition of proliferation and metastasis for lung cancer cells.
BMC Cancer. 2024;24:248.
PubMed Abstract available

LANG Y, Lin Y, Deng M, Liu X, et al
Economic evaluation of cemiplimab plus chemotherapy regimen for advanced non-small-cell lung cancer.
BMC Cancer. 2024;24:236.
PubMed Abstract available

CHENG WC, Lin CC, Liao WC, Lin YC, et al
The difference between dacomitinib and afatinib in effectiveness and safety in first-line treatment of patients with advanced EGFR-mutant non-small cell lung cancer: a real-world observational study.
BMC Cancer. 2024;24:228.
PubMed Abstract available

HUANG CY, Hsieh MS, Hsieh PC, Wu YK, et al
Pulmonary rehabilitation improves exercise capacity, health-related quality of life, and cardiopulmonary function in patients with non-small cell lung cancer.
BMC Cancer. 2024;24:211.
PubMed Abstract available

THAMRONGJIRAPAT T, Muntham D, Incharoen P, Trachu N, et al
Molecular alterations and clinical prognostic factors in resectable non-small cell lung cancer.
BMC Cancer. 2024;24:200.
PubMed Abstract available

YIN H, Jia W, Yu J, Zhu H, et al
Radiation pneumonitis after concurrent aumolertinib and thoracic radiotherapy in EGFR-mutant non-small cell lung cancer patients.
BMC Cancer. 2024;24:197.
PubMed Abstract available

FARAMARZI S, Kiani B, Faramarzi S, Firouraghi N, et al
Cancer patterns in Iran: a gender-specific spatial modelling of cancer incidence during 2014-2017.
BMC Cancer. 2024;24:191.
PubMed Abstract available

SHIM YB, Oh BC, Lee EK, Park MH, et al
Comparison of partitioned survival modeling with state transition modeling approaches with or without consideration of brain metastasis: a case study of Osimertinib versus pemetrexed-platinum.
BMC Cancer. 2024;24:189.
PubMed Abstract available

WANG Y, Ren H
Multi-omics sequencing revealed endostar combined with cisplatin treated non small cell lung cancer via anti-angiogenesis.
BMC Cancer. 2024;24:187.
PubMed Abstract available

ZHAO M, Shao T, Shao H, Zhou C, et al
Identifying optimal ALK inhibitors in first- and second-line treatment of patients with advanced ALK-positive non-small-cell lung cancer: a systematic review and network meta-analysis.
BMC Cancer. 2024;24:186.
PubMed Abstract available

ELSHAMI M, Sawafta N, Mansour A, Alser M, et al
Anticipated time to seek medical advice for possible lung cancer symptoms and barriers to timely presentation in Palestine: a national cross-sectional study.
BMC Cancer. 2024;24:183.
PubMed Abstract available

YAN N, Zhang H, Shen S, Guo S, et al
Response to immune checkpoint inhibitor combination therapy in metastatic RET-mutated lung cancer from real-world retrospective data.
BMC Cancer. 2024;24:178.
PubMed Abstract available

PHAM CP, Nguyen TTH, Do AT, Nguyen TK, et al
A real-world cohort study of first-line afatinib in patients with EGFR-mutant advanced non-small cell lung cancer in Vietnam.
BMC Cancer. 2024;24:176.
PubMed Abstract available

WU J, Zhou Y, Xu C, Yang C, et al
Effectiveness of CT radiomic features combined with clinical factors in predicting prognosis in patients with limited-stage small cell lung cancer.
BMC Cancer. 2024;24:170.
PubMed Abstract available

January 2024

SHIN S, Moon J, Oum C, Kim S, et al
Discontinuation risk from adverse events: immunotherapy alone vs. combined with chemotherapy: a systematic review and network meta-analysis.
BMC Cancer. 2024;24:152.
PubMed Abstract available

DONG W, Yin Y, Yang S, Liu B, et al
Impact of chronic obstructive pulmonary disease on the efficacy and safety of neoadjuvant immune checkpoint inhibitors combined with chemotherapy for resectable non-small cell lung cancer: a retrospective cohort study.
BMC Cancer. 2024;24:153.
PubMed Abstract available

XUE M, Liu J, Li Z, Lu M, et al
The role of adenocarcinoma subtypes and immunohistochemistry in predicting lymph node metastasis in early invasive lung adenocarcinoma.
BMC Cancer. 2024;24:139.
PubMed Abstract available

LIU JS, Cai YX, He YZ, Xu J, et al
Spatial and temporal heterogeneity of tumor immune microenvironment between primary tumor and brain metastases in NSCLC.
BMC Cancer. 2024;24:123.
PubMed Abstract available

ZHANG Y, Zhang C, He M, Xing W, et al
Co-expression of IL-21-Enhanced NKG2D CAR-NK cell therapy for lung cancer.
BMC Cancer. 2024;24:119.
PubMed Abstract available

QIAN J, He Z, Wu Y, Li H, et al
Analysis of the efficacy of upfront brain radiotherapy versus deferred radiotherapy for EGFR/ALK-positive non-small cell lung cancer with brain metastases: a retrospective study.
BMC Cancer. 2024;24:117.
PubMed Abstract available

LI R, Liang H, Li J, Shao Z, et al
Paclitaxel liposome (Lipusu) based chemotherapy combined with immunotherapy for advanced non-small cell lung cancer: a multicenter, retrospective real-world study.
BMC Cancer. 2024;24:107.
PubMed Abstract available

JIA QC, Qin L, Niu Y, Liu L, et al
Red blood cell distribution width is associated with sarcopenia risk in early-stage non-small cell lung cancer.
BMC Cancer. 2024;24:95.
PubMed Abstract available

QIN B, Xin L, Liang C, Li L, et al
Efficacy and safety of anti-PD-1 inhibitor versus anti-PD-L1 inhibitor in first-line treatment of extensive-stage small cell lung cancer: a multicenter retrospective study.
BMC Cancer. 2024;24:100.
PubMed Abstract available

LIU W, Du Q, Mei T, Wang J, et al
Comprehensive analysis the prognostic and immune characteristics of mitochondrial transport-related gene SFXN1 in lung adenocarcinoma.
BMC Cancer. 2024;24:94.
PubMed Abstract available

LI J, Li L, Tang S, Yu Q, et al
Novel model integrating computed tomography-based image markers with genetic markers for discriminating radiation pneumonitis in patients with unresectable stage III non-small cell lung cancer receiving radiotherapy: a retrospective multi-center radio
BMC Cancer. 2024;24:78.
PubMed Abstract available

ZHAO Z, Gu S, Yang Y, Wu W, et al
A cost-effectiveness analysis of lung cancer screening with low-dose computed tomography and a polygenic risk score.
BMC Cancer. 2024;24:73.
PubMed Abstract available

YANO Y, Abnet CC, Roshandel G, Graf A, et al
Dental health and lung cancer risk in the Golestan Cohort Study.
BMC Cancer. 2024;24:74.
PubMed Abstract available

KIM TH, Choi JH, Ahn MS, Lee HW, et al
Differential efficacy of tyrosine kinase inhibitors according to the types of EGFR mutations and agents in non-small cell lung cancer: a real-world study.
BMC Cancer. 2024;24:70.
PubMed Abstract available

CHEN C, Liu H, Li Y, Xu Q, et al
Downregulation of PTPRT elevates the expression of survivin and promotes the proliferation, migration, and invasion of lung adenocarcinoma.
BMC Cancer. 2024;24:63.
PubMed Abstract available

LIU B, Feng Y, Xie N, Yang Y, et al
FERMT1 promotes cell migration and invasion in non-small cell lung cancer via regulating PKP3-mediated activation of p38 MAPK signaling.
BMC Cancer. 2024;24:58.
PubMed Abstract available

YAN M, Kang W, Liu X, Yang B, et al
Prognostic value of plasma microRNAs for non-small cell lung cancer based on data mining models.
BMC Cancer. 2024;24:52.
PubMed Abstract available

LU Y, He W, Huang X, Xiao X, et al
Pulsatilla saponin D regulates ras-related C3 botulinum toxin substrate 3 (RAC3) to overcome resistance to paclitaxel in lung adenocarcinoma cells.
BMC Cancer. 2024;24:55.
PubMed Abstract available

AI F, Zhao J, Yang W, Wan X, et al
Estimating smoking-attributable lung cancer mortality in Chinese adults from 2000 to 2020: a comparison of three methods.
BMC Cancer. 2024;24:47.
PubMed Abstract available

CHEN LD, Lin L, Chen JZ, Song Y, et al
Identification of key genes in chronic intermittent hypoxia-induced lung cancer progression based on transcriptome sequencing.
BMC Cancer. 2024;24:41.
PubMed Abstract available

GUO M, Cao Z, Huang Z, Hu S, et al
The value of CT shape quantification in predicting pathological classification of lung adenocarcinoma.
BMC Cancer. 2024;24:35.
PubMed Abstract available

LIU Y, Han T, Miao R, Zhou J, et al
RACGAP1 promotes the progression and poor prognosis of lung adenocarcinoma through its effects on the cell cycle and tumor stemness.
BMC Cancer. 2024;24:7.
PubMed Abstract available

ZHAO S, Miao M, Wang Q, Zhao H, et al
The current status of clinical trials on cancer and age disparities among the most common cancer trial participants.
BMC Cancer. 2024;24:30.
PubMed Abstract available

WANG XC, Zhang L, Lin JB, Huang XY, et al
Imaging diagnosis and differential diagnosis of extraskeletal osteosarcoma.
BMC Cancer. 2024;24:11.
PubMed Abstract available

ZHOU F, Wang M, Wang Z, Li W, et al
Screening of novel tumor-associated antigens for lung adenocarcinoma mRNA vaccine development based on pyroptosis phenotype genes.
BMC Cancer. 2024;24:28.
PubMed Abstract available

December 2023

DU C, Chen Y, Zhou Y, Zheng D, et al
Neo-adjuvant chemotherapy plus immunotherapy in resectable N1/N2 NSCLC.
BMC Cancer. 2023;23:1260.
PubMed Abstract available

SHEN GY, Huang RZ, Yang SB, Shen RQ, et al
High SNHG expression may predict a poor lung cancer prognosis based on a meta-analysis.
BMC Cancer. 2023;23:1243.
PubMed Abstract available

ZHENG X, Zhang L, Wu L, Zhao J, et al
Baseline C-reactive protein predicts efficacy of the first-line immune checkpoint inhibitors plus chemotherapy in advanced lung squamous cell carcinoma: a retrospective, multicenter study.
BMC Cancer. 2023;23:1244.
PubMed Abstract available

ZHANG K, Zhang T, Guo Z, Zhao F, et al
Adding simultaneous integrated boost to whole brain radiation therapy improved intracranial tumour control and minimize radiation-induced brain injury risk for the treatment of brain metastases.
BMC Cancer. 2023;23:1240.
PubMed Abstract available

VOLPE S, Zaffaroni M, Piperno G, Vincini MG, et al
Multi-omics integrative modelling for stereotactic body radiotherapy in early-stage non-small cell lung cancer: clinical trial protocol of the MONDRIAN study.
BMC Cancer. 2023;23:1236.
PubMed Abstract available

ARIMURA K, Hiroshima K, Nagashima Y, Nakazawa T, et al
LAG3 is an independent prognostic biomarker and potential target for immune checkpoint inhibitors in malignant pleural mesothelioma: a retrospective study.
BMC Cancer. 2023;23:1206.
PubMed Abstract available

WANG Y, Li L, Hu J, Zhao Y, et al
Comparison of efficacy and safety between PD-1 inhibitors and PD-L1 inhibitors plus platinum-etoposide as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, real-world analysis.
BMC Cancer. 2023;23:1196.
PubMed Abstract available

SONG Z, Ma H, Sun H, Li Q, et al
Construction and validation of a nomogram to predict the overall survival of small cell lung cancer: a multicenter retrospective study in Shandong province, China.
BMC Cancer. 2023;23:1182.
PubMed Abstract available

November 2023

ZHENG Q, Wang T, Jiang G, Li M, et al
Immunoglobulin superfamily 6 is a molecule involved in the anti-tumor activity of macrophages in lung adenocarcinoma.
BMC Cancer. 2023;23:1170.
PubMed Abstract available

MILLS S, Donnan P, Buchanan D, Smith BH, et al
Age and cancer type: associations with increased odds of receiving a late diagnosis in people with advanced cancer.
BMC Cancer. 2023;23:1174.
PubMed Abstract available

DE MORAES FCA, Pasqualotto E, Lopes LM, Cavalcanti Souza ME, et al
PD-1/PD-L1 inhibitors plus carboplatin and paclitaxel compared with carboplatin and paclitaxel in primary advanced or recurrent endometrial cancer: a systematic review and meta-analysis of randomized clinical trials.
BMC Cancer. 2023;23:1166.
PubMed Abstract available

LIU ZT, Shen JT, Lei YJ, Huang YC, et al
Molecular subtyping based on immune cell marker genes predicts prognosis and therapeutic response in patients with lung adenocarcinoma.
BMC Cancer. 2023;23:1141.
PubMed Abstract available

JIN S, Liu T, Wang W, Li T, et al
Lymphocyte migration regulation related proteins in urine exosomes may serve as a potential biomarker for lung cancer diagnosis.
BMC Cancer. 2023;23:1125.
PubMed Abstract available

LI S, Wang W, Yu H, Zhang S, et al
Characterization of genomic instability-related genes predicts survival and therapeutic response in lung adenocarcinoma.
BMC Cancer. 2023;23:1115.
PubMed Abstract available

SAMEJIMA H, Kojima K, Fujiwara A, Tokunaga T, et al
The combination of PD-L1 expression and the neutrophil-to-lymphocyte ratio as a prognostic factor of postoperative recurrence in non-small-cell lung cancer: a retrospective cohort study.
BMC Cancer. 2023;23:1107.
PubMed Abstract available

SUN J, Hu JR, Liu CF, Li Y, et al
ANKRD49 promotes the metastasis of NSCLC via activating JNK-ATF2/c-Jun-MMP-2/9 axis.
BMC Cancer. 2023;23:1108.
PubMed Abstract available

MISAWA S, Denda T, Kodama S, Suzuki T, et al
Efficacy and safety of mirogabalin for chemotherapy-induced peripheral neuropathy: a prospective single-arm trial (MiroCIP study).
BMC Cancer. 2023;23:1098.
PubMed Abstract available

HONG W, Zhang T, Shan C, Li H, et al
Stroke as initial manifestation of non-small cell lung cancer with Trousseau syndrome.
BMC Cancer. 2023;23:1096.
PubMed Abstract available

LOCOCO F, Boldrini L, Diepriye CD, Evangelista J, et al
Correction: Lung cancer multi-omics digital human avatars for integrating precision medicine into clinical practice: the LANTERN study.
BMC Cancer. 2023;23:1082.
PubMed

ROUSSOT N, Fumet JD, Limagne E, Thibaudin M, et al
A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer.
BMC Cancer. 2023;23:1080.
PubMed Abstract available

CHE K, Hong C, He Y, Peng D, et al
Association of immune-related adverse events with COVID-19 pneumonia in lung cancer patients receiving immune checkpoint inhibitors: a cross-sectional study in China.
BMC Cancer. 2023;23:1069.
PubMed Abstract available

ISAKA T, Adachi H, Murakami K, Miura J, et al
Preoperative predictors for recurrence sites associated with poor post-recurrence survival after surgery of non-small cell lung cancer: a multicenter study.
BMC Cancer. 2023;23:1064.
PubMed Abstract available

October 2023

WANG Y, Yu T, Chen J, Zhao R, et al
Immune characteristics analysis and construction of a four-gene prognostic signature for lung adenocarcinoma based on estrogen reactivity.
BMC Cancer. 2023;23:1047.
PubMed Abstract available

SONG Y, Lin S, Chen J, Dang J, et al
First-line treatment with TKI plus brain radiotherapy versus TKI alone in EGFR-mutated non-small cell Lung cancer with brain metastases: a systematic review and meta-analysis.
BMC Cancer. 2023;23:1043.
PubMed Abstract available

AFTAB R, Qiang Y, Zhao J, Urrehman Z, et al
Graph Neural Network for representation learning of lung cancer.
BMC Cancer. 2023;23:1037.
PubMed Abstract available

ZHANG T, Li S, Chang J, Qin Y, et al
Impact of BMI on the survival outcomes of non-small cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis.
BMC Cancer. 2023;23:1023.
PubMed Abstract available

TAFENZI HA, Choulli F, Adjade G, Baladi A, et al
Development of a well-defined tool to predict the overall survival in lung cancer patients: an African based cohort.
BMC Cancer. 2023;23:1016.
PubMed Abstract available

NAGASAKA M, Zhang SS, Baca Y, Xiu J, et al
Pan-tumor survey of ROS1 fusions detected by next-generation RNA and whole transcriptome sequencing.
BMC Cancer. 2023;23:1000.
PubMed Abstract available

KIM H, Hwang J, Kim SM, Choi J, et al
Risk factor analysis of the development of severe radiation pneumonitis in patients with non-small cell lung cancer treated with curative radiotherapy, with focus on underlying pulmonary disease.
BMC Cancer. 2023;23:992.
PubMed Abstract available

PU X, Zhou Y, Kong Y, Chen B, et al
Efficacy and safety of dacomitinib in treatment-naive patients with advanced NSCLC harboring uncommon EGFR mutation: an ambispective cohort study.
BMC Cancer. 2023;23:982.
PubMed Abstract available

ZHAO C, Tong L, Liu B, Qi F, et al
Plasma hepatocyte growth factor as a noninvasive biomarker in small cell lung cancer.
BMC Cancer. 2023;23:973.
PubMed Abstract available

YANG Z, Zhong W, Luo Y, Wu C, et al
The timing of durvalumab administration affects the risk of pneumonitis in patients with locally advanced non-small cell lung cancer: a systematic review and meta-analysis.
BMC Cancer. 2023;23:962.
PubMed Abstract available

GAO Y, Wang X, Zhao X, Zhu C, et al
Multiphase CT radiomics nomogram for preoperatively predicting the WHO/ISUP nuclear grade of small (< 4 cm) clear cell renal cell carcinoma.
BMC Cancer. 2023;23:953.
PubMed Abstract available

CHEN Y, Gong L, Gu P, Hua Y, et al
Pan-immune-inflammation and its dynamics: predictors of survival and immune-related adverse events in patients with advanced NSCLC receiving immunotherapy.
BMC Cancer. 2023;23:944.
PubMed Abstract available

WANG W, Wang S, Wang M, Ma Y, et al
Effects of TRAF3 on the proliferation and migration of lung adenocarcinoma depend partly on pyroptosis.
BMC Cancer. 2023;23:942.
PubMed Abstract available

ZHAO Z, Sun Y, Tang J, Yang Y, et al
LRPPRC regulates malignant behaviors, protects mitochondrial homeostasis, mitochondrial function in osteosarcoma and derived cancer stem-like cells.
BMC Cancer. 2023;23:935.
PubMed Abstract available

ZHANG Y, Qu H, Tian Y, Na F, et al
PB-LNet: a model for predicting pathological subtypes of pulmonary nodules on CT images.
BMC Cancer. 2023;23:936.
PubMed Abstract available

WANG Y, Pan J, An F, Chen K, et al
GBP2 is a prognostic biomarker and associated with immunotherapeutic responses in gastric cancer.
BMC Cancer. 2023;23:925.
PubMed Abstract available

AMIN A, Koul AM, Wani UM, Farooq F, et al
Dissection of paracrine/autocrine interplay in lung tumor microenvironment mimicking cancer cell-monocyte co-culture models reveals proteins that promote inflammation and metastasis.
BMC Cancer. 2023;23:926.
PubMed Abstract available

September 2023

SHAO CY, Luo J, Ju S, Li CL, et al
Online decision tools for personalized survival prediction and treatment optimization in elderly patients with lung squamous cell carcinoma: a retrospective cohort study.
BMC Cancer. 2023;23:920.
PubMed Abstract available

LI X, An W, Pan H, Fan Y, et al
Correction: Wilms' tumour gene 1 (WT1) enhances non-small cell lung cancer malignancy and is inhibited by microRNA-498-5p.
BMC Cancer. 2023;23:909.
PubMed

WAKUDA K, Kenmotsu H, Sato Y, Nakamura A, et al
Randomized, open-label phase II study of brigatinib and carboplatin plus pemetrexed and brigatinib alone for chemotherapy-naive patients with ALK-rearranged non-squamous non-small cell lung cancer: treatment rationale and protocol design of the B-DASH
BMC Cancer. 2023;23:902.
PubMed Abstract available

REN Q, Li Q, Shao C, Zhang P, et al
Establishing a prognostic model based on immune-related genes and identification of BIRC5 as a potential biomarker for lung adenocarcinoma patients.
BMC Cancer. 2023;23:897.
PubMed Abstract available

ALIMBETOV D, Umbayev B, Tsoy A, Begimbetova D, et al
Small molecule targeting of the p38/Mk2 stress signaling pathways to improve cancer treatment.
BMC Cancer. 2023;23:895.
PubMed Abstract available

ZHOU T, Wang Z, Qiao C, Wang S, et al
Sleep disturbances and the risk of lung cancer: a meta-epidemiological study.
BMC Cancer. 2023;23:884.
PubMed Abstract available

LIAO Z, Zheng R, Li N, Shao G, et al
Development and validation of a risk model with variables related to non-small cell lung cancer in patients with pulmonary nodules: a retrospective study.
BMC Cancer. 2023;23:872.
PubMed Abstract available

BHAT GR, Jamwal RS, Sethi I, Bhat A, et al
Associations between telomere attrition, genetic variants in telomere maintenance genes, and non-small cell lung cancer risk in the Jammu and Kashmir population of North India.
BMC Cancer. 2023;23:874.
PubMed Abstract available

SIMIENE J, Dabkeviciene D, Stanciute D, Prokarenkaite R, et al
Potential of miR-181a-5p and miR-630 as clinical biomarkers in NSCLC.
BMC Cancer. 2023;23:857.
PubMed Abstract available

CHEN CL, Wang ST, Liao WC, Chen CH, et al
A real-world study comparing perioperative chemotherapy and EGFR-tyrosine kinase inhibitors for treatment of resected stage III EGFR-mutant adenocarcinoma.
BMC Cancer. 2023;23:847.
PubMed Abstract available

SON SM, Yun J, Kim DW, Jung YS, et al
MicroRNA 29a therapy for CEACAM6-expressing lung adenocarcinoma.
BMC Cancer. 2023;23:843.
PubMed Abstract available

KANAOKA K, Sumikawa H, Oyamada S, Tamiya A, et al
Osteoblastic bone reaction in non-small cell lung cancer harboring epidermal growth factor receptor mutation treated with osimertinib.
BMC Cancer. 2023;23:834.
PubMed Abstract available

ROH J, Kim B, Im M, Jang W, et al
MALAT1-regulated gene expression profiling in lung cancer cell lines.
BMC Cancer. 2023;23:818.
PubMed Abstract available

CHENG G, Wu J, Ji M, Hu W, et al
TET2 inhibits the proliferation and metastasis of lung adenocarcinoma cells via activation of the cGAS-STING signalling pathway.
BMC Cancer. 2023;23:825.
PubMed Abstract available

LI X, An W, Pan H, Fan Y, et al
Wilms' tumour gene 1 (WT1) enhances non-small cell lung cancer malignancy and is inhibited by microRNA-498-5p.
BMC Cancer. 2023;23:824.
PubMed Abstract available

CAI JS, Yang F, Wang X
Occult lymph node metastasis is not a favorable factor for resected NSCLC patients.
BMC Cancer. 2023;23:822.
PubMed Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.